RT Journal Article
SR Electronic
T1 Breast and prostate cancer risk: the interplay of polygenic risk, high-impact monogenic variants, and family history
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.04.21258277
DO 10.1101/2021.06.04.21258277
A1 Emadeldin Hassanin
A1 Patrick May
A1 Rana Aldisi
A1 Isabel Spier
A1 Andreas J. Forstner
A1 Markus M. Nöthen
A1 Stefan Aretz
A1 Peter Krawitz
A1 Dheeraj Reddy Bobbili
A1 Carlo Maj
YR 2021
UL http://medrxiv.org/content/early/2021/06/09/2021.06.04.21258277.abstract
AB Purpose Investigate to which extent polygenic risk scores (PRS), high-impact monogenic variants, and family history affect breast and prostate cancer risk by assessing cancer prevalence and cancer cumulative lifetime incidence.Methods 200,643 individuals from the UK Biobank were stratified as follows: 1. carriers or non-carriers of high impact constitutive, monogenic variants in cancer susceptibility genes, 2. high or non-high PRS (90th percentile threshold), 3. with or without a family history of cancer.Multivariable logistic regression was used to compare the odds ratio (OR) across the different groups while Cox proportional hazards models were used to compute the cumulative incidence through life.Results Breast and prostate cancer cumulative incidence by age 70 is 7% and 5% for non-carriers with non-high PRS and reaches 37% and 32% among carriers of high-impact variants in cancer susceptibility genes with high PRS.The additional presence of family history is associated with a further increase of the risk of developing cancer reaching an OR of 14 and 21 for breast and prostate cancer, respectively.Conclusion High PRS confers a cancer risk comparable to high-impact monogenic variants. Family history, monogenic variants, and PRS contribute additively to breast and prostate cancer risk.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPatrick May was supported by the Luxembourg National Research Fund (FNR) as part of the National Centre of Excellence in Research on Parkinson disease (NCER-PD/FNR11264123) and the DFG Research Units FOR2715 (INTER/DFG/17/11583046) and FOR2488 (INTER/DFG/19/14429377). Carlo Maj and Emadeldin Hassanin are supported by the BONFOR-program of the Medical Faculty University of Bonn (O-147.0002). Stefan Aretz and Isabel Spier are members of the European Reference Network on Genetic Tumor Risk Syndromes (ERN GENTURIS) -Project ID No 739547. The authors acknowledge the use of de.NBI cloud and the support by the High Performance and Cloud Computing Group at the Zentrum for Datenverarbeitung of the University of Tubingen and the Federal Ministry of Education and Research (BMBF) through grant no 031A535A.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:all ethical guidelines have been followedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenome-wide genotyping data, exome-sequencing data, and phenotypic data from the UK Biobank are available upon successful project application. https://www.ukbiobank.ac.uk/